Contact us Demo our platform

METABOLON @

ESHG Annual Meeting 2024 –
European Society of Human Genetics

  • CityCube Berlin, Berlin, Germany
  • Booth 660
  • June 1 - June 4 2024

Metabolon is pleased to exhibit at the 57th annual European Human Genetics Conference.

The ESHG conference provides a platform for disseminating the most recent advancements in the field of human genetics, both scientifically and technologically. The conference provides a unique opportunity to meet, share results, and build scientific projects and collaborations.

Metabolon is pleased to have the opportunity to engage with leading researchers, clinicians, and industry experts from around the globe, sharing insights into our transformative metabolomics platform and its applications in unraveling the complexities of human health and disease.

Metabolomics and genomics are complementary disciplines that together offer a more comprehensive understanding of biological systems. While genomics focuses on studying the complete set of genes (the genome) within an organism, metabolomics examines the complete set of small molecule metabolites (the metabolome) present in a biological sample.

Join us to discover more about the complementary role metabolomics plays alongside genomics workflows!

For more event information, you can read visit the official event website or read the official program.

Join us at Booth No. 660

Join us at booth 660 to discover how Metabolon’s metabolomics services can advance your research. Schedule a meeting here to guarantee 1:1 time with a metabolomics expert.

Poster Details

Title: Evaluating Global Metabolomics Profiling as A Diagnostic Tool For Rare Diseases
Date: Monday, June 3, 2024 3:45 – 4:45 pm
Location: Poster Hall
Session: PV04
Poster No. P15.095.D

Event Location

Messe Berlin, CityCube
Messedamm 26
14055 Berlin
Germany
Google Maps

Why Metabolomics: Your Guide to Metabolomics

In this guide, we explore the ins and outs of one of the most powerful omics tools in any scientist’s toolbox, one that can complement any existing workflow and help realize the full potential of other omics methods: metabolomics.

Read now

Schedule a Meeting

Meet the Reps Attending ESHG 2024

Adam Kennedy, Ph.D.

Adam Kennedy, Ph.D.

Director, Research and Development, Clinical Metabolomics

Dr. Adam Kennedy, Ph.D., serves as the Director of Research and Development in Clinical Metabolomics at Metabolon, Inc. With a background in biochemistry and immunology, he boasts nearly 60 peer-reviewed publications and holds 5 patents, both awarded and pending. Dr. Kennedy’s career spans impactful roles including research at the National Institutes of Health (NIH), where he contributed to understanding the dissemination of S. aureus strains globally, and at the University of Virginia focusing on antibody therapies for leukemia/lymphoma.

Since joining Metabolon in 2010, Dr. Kennedy has directed over 200 projects and spearheaded the development of Metabolon’s inborn errors of metabolism screen utilizing global untargeted biochemical profiling. Leading a team of scientists, he has pioneered a rare disease screening test resulting in over 20 peer-reviewed publications and the identification of over 100 disease signatures. Dr. Kennedy’s contributions extend to initiatives for CLIA/CAP-validated tests targeting insulin resistance and impaired glucose tolerance. Through collaborative research in metabolic engineering, inflammation, and bioprocessing/cell culture analyses, Dr. Kennedy continues to advance interdisciplinary projects, showcasing his expertise in bridging research and development in clinical metabolomics.

Greg Michelotti, Ph.D.

Greg Michelotti, Ph.D.

Director, International Population Health

Dr. Greg Michelotti is the Director of International Population Health at Metabolon, Inc., the global leader in metabolomics that offers the world’s largest metabolomics knowledge base. Dr. Michelotti earned his doctoral degree in biochemistry from the University of South Carolina and applied this training to elucidate the molecular mechanisms underpinning multi-organ stress response pathways. Since joining Metabolon, Dr. Michelotti leads biology efforts to identify metabolic signatures of disease in large human population cohorts to accelerate our understanding of the metabolic basis of human health and the transition to pathologic states. Before joining Metabolon, Dr. Michelotti led a translational research laboratory at Duke University incorporating a multi-omics approach to understand the molecular basis of liver disease and NASH progression. Collectively, his work has generated over 90 primary, peer-reviewed research publications, resulting in an h-index of 39. 

Tim Delany

Tim Delany

Corporate Development Director

With extensive experience in clinical partnerships, Tim focuses his time developing key strategic multiomic collaborations. Prior to his time at Metabolon, Tim oversaw largescale population genomic projects (Genuity Science), consulted for pharma (Merck KGaA via S3 Group) and contributed to scaling up health tech start-ups (HealthFounders, TickerFit, Cortechs). Tim earned his MSc in Biotechnology & Business at UCD Michael Smurfit. 

Brenan Durainayagam, Ph.D.

Brenan Durainayagam, Ph.D.

Product Manager

Brenan is a Product Manager at Metabolon, specializing in strategic oversight and end-to-end management of the company’s product portfolio. He steers product strategy and development while also identifying competitive differentiators and assessing market opportunities. Brenan leverages a decade of metabolomics research experience with business expertise such as financial forecasts, including discounted cash flow analyses, to make informed strategic decisions to drive product success.

Patrick Arnott, Ph.D.

Patrick Arnott, Ph.D.

Business Development Executive

With a robust background in academia, Patrick brings a wealth of experience to his role at Metabolon. His tenure in academia was marked by numerous publications and successful grant acquisitions, attesting to his expertise and dedication. Patrick’s forte lies in optimizing project costs without compromising quality, making him an invaluable asset in translating research endeavors into pioneering discoveries. His commitment to driving innovation makes him the ideal partner to elevate your projects to new heights with Metabolon. 

Zoltan Bognar

Zoltan Bognar

Business Development Executive

Zoltan has over 25 years of experience providing researchers with services and products in various research fields in life sciences. He possesses strong skills in providing research-related services and offers both our preclinical and clinical analysis solutions to academic and industrial clients. Based in Berlin, he serves as your contact person in the DACH region. 

✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.